Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma

Table 5

Patients with cutaneous melanoma after first ipilimumab.

Patient	OS (months)	Status	Following therapies
2	11, 6	Dead	None
4	35, 1	Dead	None
8	85, 8	Dead	None
14	57, 4+	No evidence of disease	None
16	88, 3+	No evidence of disease	Anti-PD-1
18	77, 3+	Alive with disease	Anti-PD-1; MEK inhibitor combined with BRAF-inhibitor
19	15, 3	Dead	None
20	133, 5+	No evidence of disease	None
21	52, 7	Lost to follow-up	Unknown
22	80, 5+	No evidence of disease	None

MEK inhibitor was discontinued due to retinal vein occlusion.